Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Angiogenesis and Fibrosis Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PDGF-BB drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PDGF-BB Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View PDGF-BB Products |
| Gene Delivery | PDGF-BB Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View PDGF-BB Products |
| Benchmark Ab | Anti-PDGF-BB (Sequence of Pegpleranib/Aptamer-analog) Recombinant positive control. |
View PDGF-BB Products |
| Validator | PDGF-BB siRNA Set For knockdown verification. |
View PDGF-BB Products |
| Related Target A | PDGFRB Primary signaling receptor for PDGF-BB driving pericyte recruitment. |
View PDGFRB Products |
| Related Target B | VEGFA Synergistic target for anti-angiogenic combination therapies in ophthalmology. |
View VEGFA Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Receptor Binding Assays | HEK293 Expressed (Native Glycosylation and Disulfide bond formation) ensuring proper homodimerization. |
| Cross-species Translation | Human/Mouse/Cyno ortholog proteins available with >95% purity and Theoretical MW confirmation. |
| Lack of Controls | Clinical Benchmark Antibodies included for direct competitive assay design. |
| False Positives | Validated siRNA included for specificity checks in cellular microenvironment models. |
Live PDGF-BB R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PDGF-BB therapeutics is intensifying, with major players shifting focus from traditional wound-healing topicals to advanced combination therapies in ophthalmology and oncology. As first-generation therapies reach the clinic, the next wave of R&D is targeting the synergistic blockade of VEGF and PDGF pathways to overcome anti-VEGF resistance in neovascular age-related macular degeneration (nAMD), alongside novel fibrosis inhibitors modulating the tumor microenvironment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Aptamers / mAbs | Ophthotech (Iveric Bio), Novartis | Neovascular AMD | Neutralization Assay (Need high-purity Homodimers) |
| Recombinant Protein | Smith & Nephew (Regranex) | Diabetic Foot Ulcers | Quality Control (Need Endotoxin Controlled standards) |
| Bispecifics (Anti-VEGF/PDGF) | Various Preclinical | Refractory Angiogenesis | Heterodimer Validation (Need Cross-reactive Abs) |
| Small Molecules (TKIs) | Pfizer, Bayer (Receptor-targeted) | Oncology, Fibrosis | Selectivity Assay (Need Ligand-induced activation controls) |